From Fierce Pharma
While much of the world has moved on to the latest headline-grabbing outbreak in Zika, Merck continues to press on with its Ebola vaccine candidate. On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.
With both designations, the vaccine is set to receive additional regulatory support in its push toward licensure thanks to promising clinical data and a potential to best current Ebola options. Merck plans to submit the vaccine for approval by the end of 2017 as part of a partnership with Gavi that will see the Vaccine Alliance pay $5 million to build a stockpile.